Tyra Biosciences (NASDAQ:TYRA) Posts Earnings Results, Misses Estimates By $0.02 EPS

Tyra Biosciences (NASDAQ:TYRA) issued its quarterly earnings data on Tuesday. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.02), Zacks reports.

Tyra Biosciences Price Performance

Shares of NASDAQ:TYRA traded up $0.49 during midday trading on Tuesday, reaching $32.53. The company had a trading volume of 347,643 shares, compared to its average volume of 910,415. The stock’s fifty day moving average price is $30.47 and its 200-day moving average price is $32.71. Tyra Biosciences has a one year low of $9.96 and a one year high of $40.65. The stock has a market capitalization of $1.93 billion, a P/E ratio of -14.92 and a beta of 0.77.

Analyst Ratings Changes

Several research analysts recently weighed in on TYRA shares. Canaccord Genuity Group initiated coverage on shares of Tyra Biosciences in a research note on Monday, April 6th. They issued a “buy” rating and a $50.00 target price for the company. Wolfe Research started coverage on shares of Tyra Biosciences in a report on Tuesday, May 19th. They set a “peer perform” rating for the company. Bank of America boosted their price objective on shares of Tyra Biosciences from $37.00 to $42.00 and gave the company a “buy” rating in a research report on Wednesday, June 10th. HC Wainwright restated a “buy” rating and issued a $45.00 price objective on shares of Tyra Biosciences in a report on Thursday, May 14th. Finally, Guggenheim initiated coverage on Tyra Biosciences in a report on Tuesday, April 14th. They set a “buy” rating and a $54.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Tyra Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $47.00.

Hedge Funds Weigh In On Tyra Biosciences

Institutional investors have recently made changes to their positions in the stock. Commodore Capital LP boosted its position in Tyra Biosciences by 226.3% during the 2nd quarter. Commodore Capital LP now owns 3,100,000 shares of the company’s stock valued at $29,667,000 after purchasing an additional 2,150,000 shares during the period. Janus Henderson Group PLC lifted its stake in Tyra Biosciences by 2.1% in the fourth quarter. Janus Henderson Group PLC now owns 2,935,442 shares of the company’s stock valued at $77,085,000 after buying an additional 60,638 shares during the last quarter. Farallon Capital Management LLC boosted its holdings in shares of Tyra Biosciences by 80.7% during the fourth quarter. Farallon Capital Management LLC now owns 2,066,818 shares of the company’s stock valued at $54,337,000 after acquiring an additional 923,000 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Tyra Biosciences by 8.5% during the third quarter. Vanguard Group Inc. now owns 1,520,185 shares of the company’s stock valued at $21,267,000 after acquiring an additional 118,492 shares during the period. Finally, Caligan Partners LP grew its position in shares of Tyra Biosciences by 35.5% during the fourth quarter. Caligan Partners LP now owns 944,257 shares of the company’s stock worth $24,825,000 after acquiring an additional 247,432 shares during the last quarter. 84.14% of the stock is owned by institutional investors.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.